Strides Pharma Science's Q3 FY 2025-26 Quarterly Results
- 31 Jan 2026
Result Summary
- Strides Pharma Science Ltd reported a 4.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 12.3%.
- Its expenses for the quarter were down by 3.0% QoQ and up 0.8% YoY.
- The net profit increased 58.2% QoQ and increased 131.2% YoY.
- The earnings per share (EPS) of Strides Pharma Science Ltd stood at 21.92 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 1301.51 | 1247.97 | 1159.28 | 4.3% | 12.3% |
Total Expenses | 1052.70 | 1085.03 | 1043.96 | -3.0% | 0.8% |
Profit Before Tax | 245.51 | 154.16 | 112.89 | 59.3% | 117.5% |
Tax | 37.35 | 21.59 | 23.80 | 73.0% | 56.9% |
Profit After Tax | 208.13 | 131.52 | 90.04 | 58.2% | 131.2% |
Earnings Per Share | 21.92 | 13.84 | 9.55 | 58.4% | 129.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Strides Pharma Science Ltd is a pharmaceutical company that operates in the healthcare sector. It is primarily engaged in the development, manufacturing, and marketing of pharmaceutical products. The company offers a diverse portfolio that includes prescription drugs and over-the-counter medications. Strides Pharma focuses on niche areas such as sterile injectables, and its markets span across various geographies, including regulated markets like the United States and emerging markets. As of the most recent updates, the company has been working on expanding its global footprint and enhancing its product portfolio through strategic partnerships and investments in research and development. There are no recent major developments available in the provided data.
Revenue
In Q3FY26, Strides Pharma Science Ltd reported a total income of ₹1301.51 crores, reflecting a quarter-over-quarter (QoQ) increase of 4.3% compared to Q2FY26, when the total income was ₹1247.97 crores. Year-over-year (YoY), the total income increased by 12.3% from Q3FY25's ₹1159.28 crores. This data demonstrates a positive trend in revenue generation over both the quarter and the year.
Profitability
For Q3FY26, Strides Pharma Science Ltd's profit before tax stood at ₹245.51 crores, marking a significant QoQ increase of 59.3% from the ₹154.16 crores recorded in Q2FY26. The YoY increase was even more pronounced at 117.5% compared to Q3FY25's ₹112.89 crores. The profit after tax for Q3FY26 was ₹208.13 crores, which indicates a 58.2% QoQ growth from ₹131.52 crores in Q2FY26 and a 131.2% YoY growth from ₹90.04 crores in Q3FY25. The company's earnings per share (EPS) for Q3FY26 was ₹21.92, showing a 58.4% QoQ increase from ₹13.84 in Q2FY26, and a 129.5% YoY increase from ₹9.55 in Q3FY25. The tax expense also rose by 73.0% QoQ and 56.9% YoY, reaching ₹37.35 crores in Q3FY26.
Operating Metrics
The total expenses for Strides Pharma Science Ltd in Q3FY26 were ₹1052.70 crores, which decreased by 3.0% from the previous quarter's ₹1085.03 crores. However, when compared to the same quarter in the previous year, the expenses increased slightly by 0.8% from ₹1043.96 crores in Q3FY25. The reduction in expenses on a quarter-over-quarter basis is notable, although the year-over-year change is minimal. The company's ability to manage expenses effectively while increasing revenue has positively impacted its profitability metrics, as reflected in the significant increases in profit before tax, profit after tax, and earnings per share.